Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nishanthi Thalayasingam

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Best Practice & Research. Clinical Rheumatology|December 6, 2011
Anti-TNF therapyNishanthi Thalayasingam, John D Isaacs
Expert Opinion on Therapeutic Targets|December 28, 2022
Sjögren's syndrome: shedding light on emerging and key drug targetsDominic Ridgewell, Nishanthi Thalayasingam, Wan-Fai Ng
Rheumatology (Oxford, England)|December 24, 2021
New developments in Sjogren's syndromeNishanthi Thalayasingam, Kelly Baldwin, Claire Judd, et al.
The Journal of Allergy and Clinical Immunology|January 17, 2020
Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease lociAlexander D Clark, Nisha Nair, Amy E Anderson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 2, 2017
CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis: Implications for Causal Gene IdentificationNishanthi Thalayasingam, Nisha Nair, Andrew J Skelton, et al.
Genome Biology|November 2, 2016
Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23Amanda McGovern, Stefan Schoenfelder, Paul Martin, et al.
Annals of the Rheumatic Diseases|June 9, 2022
Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogrammingFaye A H Cooles, Jessica Tarn, Dennis W Lendrem, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Best Practice & Research. Clinical Rheumatology|December 6, 2011
Anti-TNF therapyNishanthi Thalayasingam, John D Isaacs
Expert Opinion on Therapeutic Targets|December 28, 2022
Sjögren's syndrome: shedding light on emerging and key drug targetsDominic Ridgewell, Nishanthi Thalayasingam, Wan-Fai Ng
Rheumatology (Oxford, England)|December 24, 2021
New developments in Sjogren's syndromeNishanthi Thalayasingam, Kelly Baldwin, Claire Judd, et al.
The Journal of Allergy and Clinical Immunology|January 17, 2020
Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease lociAlexander D Clark, Nisha Nair, Amy E Anderson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 2, 2017
CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis: Implications for Causal Gene IdentificationNishanthi Thalayasingam, Nisha Nair, Andrew J Skelton, et al.
Genome Biology|November 2, 2016
Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23Amanda McGovern, Stefan Schoenfelder, Paul Martin, et al.
Annals of the Rheumatic Diseases|June 9, 2022
Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogrammingFaye A H Cooles, Jessica Tarn, Dennis W Lendrem, et al.
Pageof 1